Hypha Labs, Inc. (FUNI) Unveils Platform Targeting 8-Day Production, Up to 80% Cost Cuts

Amgen's Imdelltra combined with AstraZeneca's Imfinzi showed a 58% reduction in death risk for extensive-stage small cell lung cancer patients, increasing median survival to 21.1 months. The study, presented at the European Society for Medical Oncology Congress, suggests potential for Imdelltra as a first-line maintenance therapy. Imdelltra reported $288M in Q2 2023 sales and $627M in 2025 global sales.

Apple's iPhone Duo preorders sold out quickly, with resellers charging up to 4x the retail price. The delay is due to manufacturing issues, particularly with the hinge, which has a low yield rate. Apple's own website shows a shipping date of January 2027. Analysts project 6 million units sold globally in 2026, but production challenges may hinder meeting demand.

CRISPR Therapeutics (CRSP) reports promising Phase 1a trial data for CTX310, a gene-editing therapy for high LDL and TG levels, with potential market of 40M+ U.S. patients. The company also shares Casgevy's rights with Vertex (VRTX). CTX310's Phase 1b results are expected in November. CRISPR's pipeline includes other candidates like CTX611, but faces risks of setbacks and market adoption challenges.

Microsoft's Xbox reportedly turned down a $500 million Netflix deal for exclusive rights to its IP, asking for $800 million instead. Netflix withdrew the offer. Xbox denies the deal's failure, citing other partnerships and record interest in its IP. The company is now pursuing smaller deals with multiple partners. According to an industry insider, this may have led to the creation of a new cross-media department.

Moderna's INTerpath-001 trial showed improved recurrence-free and distant-metastasis-free survival for intismeran plus pembrolizumab versus pembrolizumab alone in resected melanoma. The combination had similar serious adverse event rates, with overall survival follow-up ongoing, according to the company.

Parabilis reported a 72% response rate for its drug, comparing it to published data of 41% for nirogacestat and 55.7% for varegacestat. The company plans a Phase III trial for 2027, with a regimen of 450 mg weekly followed by 300 mg every two weeks. Parabilis has aligned with the FDA on the trial design, aiming for a broad patient population and progression-free survival as the primary endpoint.